Abstract
Purpose
A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).
Methods
We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation.
Results
The infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.
Conclusion
We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
European Medicines Agency - Overview - Biosimilar medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp. Accessed 6 Aug 2018
Urquhart L (2018) Market watch: top drugs and companies by sales in 2017. Nat Rev Drug Discov 17:232. https://doi.org/10.1038/nrd.2018.42
Aronson JK, Goldacre B, Ferner RE (2018) Prescribing biosimilars. BMJ 362:k3141. https://doi.org/10.1136/bmj.k3141
Danish Regions Vederlagsfri udlevering af medicin,. http://www.regioner.dk/sundhed/medicin/vederlagsfri-udlevering-af-medicin. Accessed 26 Jun 2017
RADS anbefaling vedrørende brug af biosimilært infliximab og etanercept. http://rads.dk/media/3488/rads-notat-om-anvendelsen-af-biosimilaere-juni-2016.pdf. Accessed 23 Jul 2018
Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML, all departments of rheumatology in Denmark (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76:1426–1431. https://doi.org/10.1136/annrheumdis-2016-210742
Glintborg B, Kringelbach T, Bolstad N, Warren DJ, Eng G, Sørensen IJ, Loft AG, Hendricks O, Hansen IMJ, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen DV, Goll GL, Høgdall E, Gehin J, Enevold C, Nielsen CH, Krogh NS, Johansen JS, Hetland ML (2018) Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. Scand J Rheumatol 47:418–421. https://doi.org/10.1080/03009742.2017.1376110
Danish Medicines Agency Nyt Om Bivirkninger. Nr. 7, årgang 7, august 2016. https://laegemiddelstyrelsen.dk/da/nyheder/nyhedsbrevet-nyt-om-bivirkninger/nyt-om-bivirkninger-august-2016/~/media/DE9B53A7B08846E186A210B97381675E.ashx. Accessed 9 Aug 2018
Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M (2017) Interchangeability of Biosimilars: a European perspective. BioDrugs Auckl 31:83–91. https://doi.org/10.1007/s40259-017-0210-0
AMGROS Markedsovervågning 3. kvartal 2016. https://www.amgros.dk/viden-og-analyser/rapporteringer/markedsovervaagning/. Accessed 10 Sep 2018
Glintborg B, Sørensen J, Hetland ML (2018) Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open 4:e000710. https://doi.org/10.1136/rmdopen-2018-000710
(2018) Regioner kan spare 335 mio. kr. om året på gigtmedicin. In: Dagens Pharma. https://dagenspharma.dk/regioner-kan-335-mio-kr-om-aaret-paa-gigtmedicin/. Accessed 19 Nov 2018
Author information
Authors and Affiliations
Contributions
TBJ and HRC initiated this analysis. All authors work with rational pharmacotherapy in Denmark and cover all five Danish regions as well as the regional authorities’ pharmaceutical procurement service. DB, EAS, BKP, SEA, MMHC, LN, and HRC were key figures during the shift to biosimilars of infliximab and etanercept. TBJ, DB and HRC planned the analysis. TBJ analysed the data. All authors have critically revised the manuscript and approved the final version for publication. HRC stands as guarantor of the article. The corresponding author attests that all listed authors meet authorship criteria and that no other people meeting the criteria have been omitted.
Corresponding author
Additional information
Pharmacoeconomics
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(SVG 193 kb)
Rights and permissions
About this article
Cite this article
Jensen, T.B., Bartels, D., Sædder, E.A. et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol 76, 35–40 (2020). https://doi.org/10.1007/s00228-019-02765-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-019-02765-3